ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1549

Sibling Relative Risk and Heritability of Kawasaki Disease: A Nationwide Population Study in Taiwan

I-Jun Chou1, Chang-Fu Kuo2, Jing-Long Huang3, Chang-Teng Wu1, Shao-Hsuan Hsia1 and Hsiao-Chun Chang4, 1Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 2Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, 3Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: family studies and vasculitis, Kawasaki disease

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Kawasaki disease (KD) is an autoimmune disease involving primarily medium-sized vessels and is the leading cause of acquired cardiac disease in children. The pathogenesis is still unknown and the evidence for familial aggregation in Kawasaki disease is rare. The aims of this study was to estimate sibling relative risk (RR) and heritability of KD.

Methods:

Using data from the National Health Insurance Research Database in Taiwan, we conducted a nationwide cross-sectional study of 2,683,174 males and 2,483,901 females who were younger than 20 years in 2010. KD was defined as children < 20 years of age hospitalised with a primary or secondary diagnosis of KD between 1996 and 2010. We identified individuals with a full sibling affected by KD and compared the prevalence of the disease between individuals with and without an affected sibling. The identification of sibling of each individual was determined using the NIHRD registry for beneficiaries, which specifies relationships between the insured person who paid the insurance fee and his/her dependents and allows first-degree relatives (father, mother, son, daughter, brother, sister, twin) to be identified directly. Full siblings were identified as individuals who shared the same parents. The marginal Cox proportional hazard model with an equal follow-up time for all subjects was used to estimate RR and the 95% confidence interval (CI). This model was used to account for shared environment and case clustering within families with robust variance, and to adjust for age, place of residence, income levels and occupation. The RR was estimated for different first-degree relative categories and for the number of first-degree relatives affected by gout. Heritability (h2) was estimated using the multifactorial polygenic model. 

Results:

There were 7,443 male and 4,558 female individuals who had KD between 1996 and 2010. Individuals with an affected sibling with KD had a higher prevalence of KD (1.53%) than those without (0.23%). The risk of KD in individuals with an affected sibling was 6.39 (95% CI, 4.63–8.83) times greater than that in individuals without an affect sibling. The sibling RR (95% CI) was slightly higher among female individuals with affected siblings (6.79, 4.50–10.27) than male ones (6.11, 4.19–8.90). The heritability of KD was 0.45 (95% CI, 0.36–0.55).

Conclusion:

The present study provides population-based estimate for sibling RR and demonstrates familial aggregation of KD. The results suggest a significant genetic contribution to the KD susceptibility.


Disclosure:

I. J. Chou,
None;

C. F. Kuo,
None;

J. L. Huang,
None;

C. T. Wu,
None;

S. H. Hsia,
None;

H. C. Chang,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sibling-relative-risk-and-heritability-of-kawasaki-disease-a-nationwide-population-study-in-taiwan/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology